Home › BIO Issues Statement on Hepatitis C medicines report.
 

Keywords :   


BIO Issues Statement on Hepatitis C medicines report.

2015-12-07 14:31:08| Industrial Newsroom - All News for Today

In his statement regarding report released by Senators Grassley and Wyden, BIO Senior VP of Communications Kenneth Lisaius stated that BIO is reviewing said report in full and generally does not comment on product pricing by member companies. Lisaius added, however, that "balanced debate about the cost of groundbreaking cures" cannot narrow their focus on price but also acknowledge value provided to patients as well as overall healthcare system.

Tags: report issues statement bio

Category:Industrial Goods and Services

Latest from this category

All news
18.06A Request From the A League of Their Own Womens Special Interest Group
18.06Next MANAchat Series is Scheduled for the Week of August 5
17.06New Federal Government Filing Requirement Regarding Ownership of LLCs and Corporations
17.06Manufacturers Reps That Sell to International Customers June 26 Networking Event
17.06Avoid $591 Daily Penalty From the U.S. Treasury Department
Industrial Goods and Services »
30.06Hurricane Beryl Public Advisory Number 8A
30.06Hurricane Beryl Graphics
30.06Eastern North Pacific Tropical Weather Outlook
30.06Atlantic Tropical Weather Outlook
30.06Hurricane Beryl Update Statement
30.06Summary for Hurricane Beryl (AT2/AL022024)
30.06Hurricane Beryl Graphics
30.06Hurricane Beryl Forecast Discussion Number 8
More »